Business Context and Reporting Period
Company: Karyopharm Therapeutics Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2013
Business Stage: Clinical-stage pharmaceutical company focused on developing SINE (Selective Inhibitors of Nuclear Export) compounds, primarily the lead candidate Selinexor (KPT-330) for cancer treatment. The company has no approved products and has not generated revenue from drug sales.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2013 | Nine Months Ended Sep 30, 2013 | As of Sep 30, 2013 |
|---|---|---|---|
| Revenue | $0 | $366 | N/A |
| Net Loss | $(9,321) | $(21,801) | N/A |
| Operating Expenses | $9,321 | $22,168 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $52,928 |
| Accumulated Deficit | N/A | N/A | $(50,423) |
| Net Cash Used in Operating Activities | N/A | $(20,212) | N/A |
| Net Cash Provided by Financing Activities | N/A | $72,774 | N/A |
Note: Revenue consists solely of contract and grant revenue. The company has no commercial product sales.
Material Changes vs. Prior Period
- Revenue Decline: Contract and grant revenue dropped to $0 for the three months ended September 30, 2013, compared to $34,000 in the same period in 2012, due to the completion of grant work in Q2 2013. For the nine-month period, revenue decreased to $366,000 from $601,000.
- Expense Surge: Total operating expenses increased significantly to $9.3 million for the quarter (from $3.7 million) and $22.2 million for the nine months (from $12.3 million).
- R&D Expenses: Rose to $7.7 million (quarter) and $18.8 million (nine months), driven by increased clinical trial costs, consulting fees, and personnel costs.
- G&A Expenses: Rose to $1.6 million (quarter) and $3.4 million (nine months), primarily due to higher consulting and personnel costs.
- Liquidity Improvement: Cash and cash equivalents increased dramatically from $391,000 at December 31, 2012, to $52.9 million at September 30, 2013. This was driven by $72.8 million in net cash provided by financing activities, primarily from the sale of convertible preferred stock.
Guidance, Outlook, and Risks
Subsequent Event (IPO): In November 2013, the company completed an Initial Public Offering (IPO), selling 6.8 million shares at $16.00 per share, with an additional 1.02 million shares sold upon underwriter option exercise. Net proceeds were approximately $113.7 million. All outstanding convertible preferred stock automatically converted to common stock upon the IPO closing.
Outlook: Management expects to continue incurring significant operating losses for the foreseeable future. The company anticipates that the IPO proceeds combined with existing cash will fund operations for at least the next 30 months. Expenses are expected to increase as the company advances Selinexor through clinical trials and prepares for potential commercialization.
Key Risks:
- Development Risk: Reliance on the success of Selinexor (Phase 1) and Verdinexor (veterinary candidate). Clinical trials may fail to demonstrate safety or efficacy.
- Capital Requirements: Need for substantial additional funding to complete development and commercialization.
- Regulatory Risk: Uncertainty regarding FDA approval timelines and requirements.
- Third-Party Dependence: Reliance on contract research organizations (CROs) and contract manufacturers.
- Internal Controls: The company identified "significant deficiencies" in internal controls over financial reporting related to insufficient finance staffing, which it is remediating.
Investor Verification Checklist
- Runway Validation: Confirm the 30-month operating runway estimate based on the $113.7 million IPO proceeds plus the $52.9 million cash balance on hand.
- Clinical Progress: Verify the status of Phase 1 trials for Selinexor and the timeline for planned registration-directed trials (expected to commence in H1 2014).
- Internal Controls: Review the remediation plan for the identified significant deficiencies in internal financial controls.
- Dilution Impact: Assess the impact of the reverse stock split (1-for-3.3) and the conversion of preferred stock on share count and future dilution.
- Grant Revenue: Confirm the cessation of contract and grant revenue and the lack of near-term commercial revenue streams.